Trials / Terminated
TerminatedNCT04866056
Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF.
A Multicentric Phase I/II Study of Jaktinib Hydrochloride Tablets in Combination With Azacitidine for Injection in Patients With Myelodysplastic Syndromes(MDS) With Myelofibrosis(MF) or MDS/Myeloproliferative Neoplasms With MF
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This phase I/II trial studies how well Jaktinib and azacytidine work in treating patients with myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis. Giving Jaktinib and azacytidine may be an effective treatment for myelodysplastic syndromes with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm with myelofibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Jaktinib | Jaktinib PO BID |
| DRUG | azacitidine | Azacytidine SC |
Timeline
- Start date
- 2021-09-30
- Primary completion
- 2022-06-10
- Completion
- 2022-06-10
- First posted
- 2021-04-29
- Last updated
- 2022-12-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04866056. Inclusion in this directory is not an endorsement.